Related Experiment Videos
[Neonatal alloimmune thrombocytopenia]
Y Schechter1, I Zeides, E Shalev
1Hematology Dept., Rambam Medical Center, Haifa.
Harefuah
|December 15, 1994
Summary
Neonatal alloimmune thrombocytopenia (NAIT) is caused by maternal antibodies attacking fetal platelets. Early antibody identification and prenatal treatment are crucial for preventing severe outcomes like intracranial hemorrhage in newborns.
Area of Science:
- Immunology
- Hematology
- Perinatology
Context:
- Neonatal alloimmune thrombocytopenia (NAIT) is a significant cause of thrombocytopenia in newborns.
- It arises from feto-maternal platelet antigen incompatibility, leading to maternal antibody production against fetal platelets.
- The condition can result in severe complications, including intracranial hemorrhage and neurological damage, potentially leading to death.
Purpose:
- To characterize specific alloimmune antibodies in mothers of infants with NAIT.
- To identify the prevalence of different anti-platelet antibodies, such as anti-HPA-1a, anti-HPA-1b, anti-HPA-5a, and anti-HPA-5b.
- To report on a successful prenatal treatment strategy for NAIT.
Summary:
- Alloimmune antibodies were identified in 18 out of 29 mothers studied, with anti-HPA-1a being the most common.
- No specific antibodies were found in 11 cases, despite clinical NAIT presentation.
- Intracranial hemorrhage occurred in neonates from anti-HPA-1a and anti-HPA-1b groups, highlighting the severity of the condition.
- A case of successful prenatal treatment involving steroids, IVIG, and intraumbilical platelet transfusion for anti-HPA-1 mediated NAIT is presented.
Impact:
- This study underscores the importance of antibody screening in neonates with unexplained thrombocytopenia.
- Early diagnosis and characterization of anti-platelet antibodies can guide timely and potentially life-saving interventions.
- The successful prenatal treatment case offers a promising therapeutic approach for severe NAIT cases, improving neonatal outcomes.